臨床泌尿器科78巻11号

2024年10月発行

特集 そうだったのか腎移植―泌尿器科ジェネラリストを目指そう!

〈実践編〉

腎移植後拒絶反応―診断と治療

著者： 土本晃裕¹

所属機関： ¹九州大学医学部 包括的腎不全治療学

ページ範囲：P.878 - P.887

文献概要

▶ポイント

・腎移植の拒絶反応は，Banff分類による腎組織診断に準拠してT細胞関連型拒絶と抗体関連型拒絶に分類される．

・免疫抑制治療の進歩により，急性拒絶は減少しているが，症候性の抗体関連型拒絶，慢性活動性T細胞型拒絶はいまだに治療抵抗性かつ予後不良である．

・服薬遵守などの予防治療に加え，早期の診断と治療介入が重要である．

参考文献

1） 日本移植学会広報委員会 : ファクトブック2023. 2024　https://www.asas.or.jp/jst/pdf/factbook/factbook2023.pdf （2024年8月1日閲覧）

2） Lentine KL, et al : OPTN/SRTR 2021 Annual Data Report : Kidney. Am J Transplant 23 （2 Suppl 1） : S21-S120, 2023

3） Kidney Disease : Improving Global Outcomes （KDIGO） Transplant Work Group : KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 （Suppl 3） : S1-155, 2009

4） Loupy A, et al : The Banff 2019 Kidney Meeting Report （I） : Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20 : 2318-2331, 2020

5） Nakagawa K, et al : Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification : Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant 21 : 174-185, 2021

6） Mannon RB, et al : Inflammation in areas of tubular atrophy in kidney allograft biopsies : a potent predictor of allograft failure. Am J Transplant 10 : 2066-2073, 2010

7） Hueso M, et al : Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection. Am J Pathol 176 : 1696-1704, 2010

8） Haas M, et al : The Banff 2017 Kidney Meeting Report : Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18 : 293-307, 2018

9） Ho J, et al : Effectiveness of T cell-mediated rejection therapy : A systematic review and meta-analysis. Am J Transplant 22 : 772-785, 2022

10） Amico P, et al : Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 85 : 1557-1563, 2008

11） Dragun D, et al : Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 73 : 1282-1286, 2012

12） Fichtner A, et al : Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. Pediatr Nephrol 36 : 2473-2484, 2021

13） Wan SS, et al : Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. Am J Transplant 20 : 1351-1364, 2020

14） Wiebe C, et al : Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12 : 1157-1167, 2012

15） Senev A, et al : The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation. Front Immunol 13 : 809059, 2022

16） Key T, et al : The kinetics of donor HLA class I-specific antibody absorption following a combined split liver and kidney transplant. NDT Plus 3 : 579-581, 2010

17） Opelz G, et al : Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 : 1570-1576, 2005

18） Wan SS, et al : The Treatment of Antibody-Mediated Rejection in Kidney Transplantation : An Updated Systematic Review and Meta-Analysis. Transplantation 102 : 557-568, 2018

19） Sood P, et al : Anti-CD20 Blocker Rituximab in Kidney Transplantation. Transplantation 102 : 44-58, 2018